Lilly expands affordability of Insulin Lispro InjectionLilly's Insulin Lispro Injection, 100 units/ml, will now have a 70% lower list price than Humalog U-100, starting Jan. 1, 2022. Impel NeuroPharma intros migraine treatment TrudhesaTrudhesa is launching with an end-to-end process meant to offer savings and home delivery of the treatment for acute migraines. Incyte wins FDA nod for Opzelura Opzelura is the first and only topical formulation of a Janus kinase inhibitor approved in the United States. Scynexis debuts Brexafemme Brexafemme is the first and only oral non-azole prescription medication approved by the FDA to treat vaginal yeast infection. Upsher-Smith partners with Cove to expand access to Tosymra for migraine Upsher-Smith's migraine medication Tosymra will now be offered through Cove's telemedicine platform. FDA gives BeiGene green light for new Brukinsa indication BeiGene's Brukinsa is now FDA approved for the treatment of adult patients with Waldenström’s macroglobulinemia. FDA OKs Impel NeuroPharma's Trudhesa Trudhesa is a nasal spray used for the acute treatment of migraine with or without aura in adults. Cara, Vifor receive FDA nod for Korsuva Korsuva for injection is a kappa-opioid receptor agonist that targets the body’s peripheral nervous system. FDA approves Tibsovo to treat bile duct cancer Tibsovo is the first and only targeted therapy approved for patients with previously treated IDH1-mutated cholangiocarcinoma. IBSA intros new dosing options for Tirosint-SOL With the addition of three new dosage strengths, Tirosint-SOL is now available in 15 dosage strengths. First Previous 17 18 19 20 21 Next Last
